Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas including those in metabolic disease, hematology, and immuno-oncology.
Company Details
- Employees
- 92
- Founded
- -
- Address
- 101 South Street 6th Floor, Somerville,ma 02143,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- cellarity.com
- Keywords
- Drug Discovery, Drug Development, Single Cell Technologies, AI, Artificial Intelligence, Machine Learning.
- HQ
- Somerville, MA
Cellarity Questions
Cellarity's website is cellarity.com
Cellarity's LinkedIn profile is https://www.linkedin.com/company/cellarity
Cellarity has
92 employees.
View email and phone details for 92
employees at Cellarity.
Cellarity's industry is
Biotechnology Research
Cellarity's top competitors are
Beam Therapeutics,
Flagship Pioneering,
Dyno Therapeutics,
Asimov,
Omega Therapeutics,
Tessera Therapeutics,
Senda Biosciences,
1910 Genetics,
Generate:biomedicines,
Nimbus Therapeutics.
Cellarity's categories are Biotechnology Research
Cellarity's founding year is 2017
